160
Participants
Start Date
December 13, 2023
Primary Completion Date
January 12, 2024
Study Completion Date
April 11, 2024
TB/Flu-05E
Participants will receive single intranasal injection of TB/Flu-05E vaccine in 0.5 ml, containing 7.7 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the TB10.4 and HspX antigens of M. tuberculosis
Placebo
Participants will receive single intranasal injection of physiological buffer in 0.5 ml
Pavlov First Saint Petersburg State Medical University, Saint Petersburg
Smorodintsev Research Institute of Influenza, Saint Petersburg
St. Petersburg City Polyclinic No. 34, Saint Petersburg
Pavlov First Saint Petersburg State Medical University
OTHER
St. Petersburg City Polyclinic No. 34
UNKNOWN
Research Institute of Influenza, Russia
OTHER